...
首页> 外文期刊>Anesthesia and Analgesia: Journal of the International Anesthesia Research Society >The in vitro effects of fibrinogen concentrate, factor XIII and fresh frozen plasma on impaired clot formation after 60% dilution.
【24h】

The in vitro effects of fibrinogen concentrate, factor XIII and fresh frozen plasma on impaired clot formation after 60% dilution.

机译:60%稀释后,纤维蛋白原浓缩物,XIII因子和新鲜冷冻血浆对血凝块形成受损的体外影响。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Previous investigations have shown that increasing fibrinogen concentration improves dilution-dependent impairment of clot formation. We conducted an in vitro study to explore whether substitution with fibrin-stabilizing factor XIII (FXIII) combined with fibrinogen promotes further improvement of clot formation, and whether fibrinogen administration as concentrate or fresh frozen plasma (FFP) results in comparable effects. METHODS: Blood from six healthy donors was diluted by 60% using lactated Ringer's solution. Aliquots of diluted blood samples were incubated with two different doses of fibrinogen concentrate, FXIII concentrate, the combination of both, or with two different doses of FFP. Using thrombelastometry (ROTEM) blood samples were analyzed at baseline (undiluted), after dilution and after supplementation. Variables were analyzed for changes from baseline, and effects of fibrinogen concentrate alone or combined with FXIII were compared with effects observed with corresponding FFP doses. RESULTS: After 60% in vitro dilution of blood all ROTEM parameters and global coagulation tests changed significantly. Among the substitutes tested FXIII alone had no effect, the combination with fibrinogen improved coagulation time, alpha angle and fibrinogen/fibrin polymerization significantly more than did small-dose fibrinogen alone. After substituting fibrinogen, median values of all ROTEM variables were within the normal range, thereby showing dose dependency but also significant differences (P = 0.027) from corresponding FFP doses (EXTEM MCF FFP small dose [38 (35, 40.3) mm)], which enabled only coagulation time to be shortened to baseline levels. CONCLUSIONS: Supplementation of fibrinogen restored all ROTEM parameters after dilution. This effect was partially enhanced by adding FXIII and was significantly stronger than for FFP substitution.
机译:背景:以前的研究表明,增加血纤蛋白原的浓度可以改善血栓形成的稀释依赖性损害。我们进行了一项体外研究,探讨用纤维蛋白稳定因子XIII(FXIII)替代纤维蛋白原替代是否能促进血凝块形成的进一步改善,以及以浓缩液或新鲜冰冻血浆(FFP)施用纤维蛋白原的效果如何。方法:使用乳酸林格氏液将六名健康供体的血液稀释60%。将稀释的血液样品的等分试样与两种不同剂量的纤维蛋白原浓缩物,FXIII浓缩物,两者的组合或两种不同剂量的FFP一起孵育。使用血栓弹力测定法(ROTEM),在基线(未稀释),稀释后和补充后分析血样。分析变量相对于基线的变化,并将纤维蛋白原浓缩物单独使用或与FXIII联合使用的效果与相应FFP剂量下的效果进行比较。结果:在体外稀释60%的血液后,所有ROTEM参数和整体凝血测试均发生了显着变化。在单独测试的替代品中,单独使用FXIII无效,与单独使用小剂量纤维蛋白原相比,与纤维蛋白原的组合可显着提高凝血时间,α角和纤维蛋白原/纤维蛋白聚合。取代纤维蛋白原后,所有ROTEM变量的中值均在正常范围内,从而显示出剂量依赖性,但与相应的FFP剂量(EXTEM MCF FFP小剂量[38(35,40.3)mm])也存在显着差异(P = 0.027),从而仅将凝血时间缩短到基线水平。结论:稀释后补充纤维蛋白原可恢复所有ROTEM参数。通过添加FXIII,此效果得到了部分增强,并且明显强于FFP替代。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号